디지털 바이오마커 시장 : 세계 전망과 예측(2024-2029년)

The global digital biomarkers market was valued at USD 2.49 billion in 2023 and is expected to grow at a CAGR of 22.86% from 2023 to 2029.

MARKET TRENDS & DRIVERS

Rise in Digitized Virtual Clinical Research

The rise in digitized virtual clinical research is a significant trend in the global digital biomarkers market, driven by advances in remote monitoring technologies and the need for more efficient, patient-centric clinical trials. This trend allows for greater patient participation and real-world data collection, accelerating the development and validation of digital biomarkers for various healthcare applications.

Increasing Focus on Drug Development Using Digital Biomarkers

The global digital biomarkers market is witnessing a notable trend with an increasing focus on drug development. Pharmaceutical and biotech companies are leveraging digital biomarkers to enhance clinical trials, improve patient recruitment, and expedite the development of new therapies, harnessing the power of real-time data for evidence-based decision-making. This trend represents a significant shift towards more efficient and data-driven drug development processes, benefiting patients and the pharmaceutical industry.

Expanding Applications of Digital Biomarkers in Mental Health

The digital markers are increasingly used to monitor and analyze behavioral patterns, providing valuable insights into stress levels, mood fluctuations, and sleep quality, supporting the proactive management of mental health conditions. This trend reflects the broader shift towards personalized, data-driven mental healthcare.

Growing Collaborations & Partnerships Among Vendors

A prominent trend in the global digital biomarkers market is the increasing number of vendor collaborations and partnerships. These partnerships combine expertise, technologies, and resources, fostering innovation and expanding the application of digital biomarkers across various healthcare sectors, ultimately benefiting patients and healthcare systems.

Rise in Aging Population & Prevalence of Chronic Diseases

The aging population and the increasing prevalence of chronic diseases have become pivotal drivers of the market. As the elderly demographic expands and chronic conditions become more widespread, there is a growing need for digital solutions that enable remote monitoring, early detection, and personalized health management, making digital biomarkers an essential component of modern healthcare.

Advancements in Remote Patient Monitoring

Advancements in remote patient monitoring, enabled by digital biomarkers, are revolutionizing healthcare by providing real-time patient data, enhancing early intervention, and optimizing chronic disease management. This technology-driven shift is fueling the growth of the global digital biomarkers market as it offers more personalized, efficient, and cost-effective healthcare solutions.

Growing Culture of Digital Health & Shift Toward Outpatient Care

The growing culture of digital health is fostering a shift toward outpatient care, where patients can monitor and manage their health remotely. This shift is a driving force behind the global digital biomarkers market, as digital biomarkers enable real-time patient monitoring and data-driven healthcare, improving outcomes and reducing the burden on traditional healthcare facilities.

SEGMENTATION INSIGHTS

INSIGHTS BY PRODUCT TYPE

The global digital biomarkers market by product type is segmented into wearables & sensors and mobile applications & software. The wearables & sensors segment dominated the segmental share in 2023 and is expected to register the highest segmental CAGR in the global digital biomarkers market during the forecast period. Wearable devices include smartwatches, fitness trackers, and other sensor-equipped devices that collect continuous health data, such as heart rate, activity levels, and sleep patterns. Wearables are a primary source of physiological data, providing insights into various health parameters. They are crucial in remote patient monitoring, clinical trials, and preventive healthcare. Sensors measure biomarkers in bodily fluids, offering insights into various health conditions. They find applications in diagnostics, disease monitoring, and research studies.

Mobile and software applications designed for smartphones and tablets enable users to monitor and manage their health. These systems often incorporate wearable devices and sensors to collect continuous patient vital signs and health status data. They support the management of chronic diseases and post-operative care. They contribute to disease management and wellness initiatives.

Segmentation by Product Type

• Wearables & Sensors
• Mobile Application & Software

INSIGHTS BY APPLICATION

The global digital biomarkers market by application is segmented into cardiology, pulmonology, and neurology. In 2023, cardiology accounted for a significant segmental share of the global market, followed by pulmonology, neurology, and others. Cardiology has witnessed significant advancements, leading to a better understanding of cardiovascular diseases (CVDs) and improved diagnostic and treatment options. Digital biomarkers have recently emerged as a revolutionary tool transforming the cardiology landscape. Digital biomarkers are measurable, physiological, behavioral, or molecular data that can be collected and analyzed using digital health technologies. These biomarkers offer new ways to diagnose, monitor, and treat CVDs, ultimately improving patient outcomes and enhancing healthcare efficiency.

Segmentation by Application

• Cardiology
• Pulmonology
• Neurology
• Others

INSIGHTS BY CLINICAL PRACTICE

The diagnostic clinical practice segment held the most prominent share of the global digital biomarkers market, accounting for over 34% in 2023. Diagnostic digital biomarkers are increasingly utilized to identify specific diseases, disorders, or physiological conditions through digital data analysis. This could involve patterns in biometric data, imaging, or other digital health inputs. Monitoring digital biomarkers involves the real-time or periodic assessment of digital data to track changes in health status, disease progression, or treatment response. Wearable devices and continuous monitoring platforms are often used. Predictive digital biomarkers help anticipate specific health events, guiding preventive measures or interventions. Predictive digital biomarkers are valuable in identifying at-risk populations.

Segmentation by Clinical Practice

• Diagnostic
• Monitoring
• Prognostic
• Predictive
• Others

INSIGHTS BY END-USERS

The global digital biomarkers market by end-user is segmented into healthcare companies, healthcare providers, and others. The healthcare companies segment held the most significant global market share in 2023. In the modern era of healthcare, integrating technology and data-driven solutions has revolutionized patient care, disease management, and drug development. Digital biomarkers, a novel concept in the field of healthcare, have gained prominence as a valuable tool for monitoring and diagnosing various medical conditions. Healthcare companies, including pharmaceutical firms and health tech startups, are increasingly recognizing the potential of digital biomarkers to improve patient outcomes and reduce costs. Another significant advantage of digital biomarkers is their potential to reduce healthcare costs. By adopting digital monitoring tools, healthcare companies can decrease the need for frequent in-person visits and hospital admissions.

Segmentation by End-users

• Healthcare Companies
• Healthcare Providers
• Others

GEOGRAPHICAL ANALYSIS

North America dominated the global digital biomarkers market share, accounting for over 46% in 2023. The market in North America is witnessing remarkable growth and innovation, driven by advancements in technology, a growing emphasis on personalized healthcare, and the increasing adoption of wearable devices and digital health solutions. Factors such as an aging population, increasing healthcare costs, and a shift towards value-based care have driven the adoption of digital biomarkers. Additionally, the COVID-19 pandemic accelerated the acceptance of remote monitoring and telehealth, further boosting the industry's growth.

Segmentation by Geography

• North America
  • The U.S.
  • Canada
• Europe
  • Germany
  • The U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
• APAC
  • Japan
  • China
  • India
  • South Korea
  • Australia
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
• Middle East & Africa
  • Turkey
  • Saudi Arabia
  • UAE
  • South Africa

VENDOR LANDSCAPE

The global digital biomarkers market is experiencing rapid growth, revolutionizing the healthcare industry by incorporating technology to collect, analyze, and interpret various digital health data. As vendors strive to develop more accurate and effective digital biomarkers, healthcare professionals gain access to advanced tools for diagnosing and managing multiple medical conditions. Ultimately, this contributes to improved patient outcomes and a more efficient healthcare system. Data privacy and security have become paramount with the increasing amount of personal health data collected. Companies that can offer robust security measures and maintain the trust of their users will have a competitive edge.

Key Company Profiles

• ActiGraph
• AliveCor
• Amgen
• Biogen
• Koneksa Health

Other Prominent Vendors

• Adherium
• Aural Analytics
• Biofourmis
• Clario
• Empatica
• Feel Therapeutics
• Gero.ai
• IXICO
• Obvio Health
• Owkin
• Precordior
• ResApp Health
• Rockley Photonics
• Sonde Health
• VivoSense

KEY QUESTIONS ANSWERED:

1. How big is the digital biomarkers market?

2. What is the growth rate of the global digital biomarkers market?

3. Which region dominates the global digital biomarkers market share?

4. What are the significant trends in the digital biomarkers industry?

5. Who are the key players in the global digital biomarkers market?

TABLE OF CONTENTS

1 SCOPE & COVERAGE

• 1.1. MARKET DEFINITION
  • 1.1.1. INCLUSIONS
  • 1.1.2. EXCLUSIONS
  • 1.1.3. MARKET ESTIMATION CAVEATS
• 1.2. MARKET BY SEGMENTATION
  • 1.2.1. MARKET BY PRODUCT TYPE
  • 1.2.2. MARKET BY APPLICATION
  • 1.2.3. MARKET BY CLINICAL PRACTICE
  • 1.2.4. MARKET BY END-USER
  • 1.2.5. MARKET SEGMENTATIONS COVERED
  • 1.2.6. REGIONS & COUNTRIES COVERED
  • 1.2.7. BASE YEAR
• 1.3. MARKET DERIVATION

2 PREMIUM INSIGHTS

• 2.1 OPPORTUNITY POCKETS
• 2.2 MARKET OPPORTUNITY BY GEOGRAPHY
• 2.3 MARKET OPPORTUNITY BY PRODUCT TYPE
• 2.4 MARKET OPPORTUNITY BY APPLICATION
• 2.5 MARKET OPPORTUNITY BY CLINICAL PRACTICE
• 2.6 MARKET OPPORTUNITY BY END-USER
• 2.7 OVERVIEW
• 2.8 GEOGRAPHY INSIGHTS
• 2.9 PRODUCT INSIGHTS
• 2.10 APPLICATION INSIGHTS
• 2.11 CLINICAL PRACTICE INSIGHTS
• 2.12 END-USER INSIGHTS

3 MARKET AT A GLANCE

4 INTRODUCTION

• 4.1 OVERVIEW

5 MARKET OPPORTUNITIES & TRENDS

• 5.1 RISE IN DIGITIZED VIRTUAL CLINICAL RESEARCH
• 5.2 INCREASING FOCUS ON DRUG DEVELOPMENT USING DIGITAL BIOMARKERS
• 5.3 EXPANDING APPLICATIONS OF DIGITAL BIOMARKERS IN MENTAL HEALTH
• 5.4 GROWING COLLABORATIONS & PARTNERSHIPS AMONG VENDORS

6 MARKET GROWTH ENABLERS

• 6.1 RISE IN AGING POPULATION & PREVALENCE OF CHRONIC DISEASES
• 6.2 ADVANCES IN REMOTE PATIENT MONITORING
• 6.3 GROWING CULTURE OF DIGITAL HEALTH & SHIFT TOWARD OUTPATIENT CARE
• 6.4 GROWING USE OF WIRELESS & WEARABLE DIGITAL MONITORING TECHNOLOGIES

7 MARKET RESTRAINTS

• 7.1 DATA SECURITY & PRIVACY CONCERN
• 7.2 LOW ADOPTION RATE
• 7.3 LACK OF REGULATORY STANDARDIZATION

8 MARKET LANDSCAPE

• 8.1 MARKET OVERVIEW
• 8.2 MARKET SIZE & FORECAST
• 8.3 FIVE FORCES ANALYSIS
  • 8.3.1 THREAT OF NEW ENTRANTS
  • 8.3.2 BARGAINING POWER OF SUPPLIERS
  • 8.3.3 BARGAINING POWER OF BUYERS
  • 8.3.4 THREAT OF SUBSTITUTES
  • 8.3.5 COMPETITIVE RIVALRY

9 PRODUCT TYPE

• 9.1 MARKET SNAPSHOT & GROWTH ENGINE
• 9.2 MARKET OVERVIEW
• 9.3 WEARABLES & SENSORS
  • 9.3.1 MARKET OVERVIEW
  • 9.3.2 MARKET SIZE & FORECAST
  • 9.3.3 WEARABLES & SENSORS MARKET BY GEOGRAPHY
• 9.4 MOBILE APPLICATION & SOFTWARE
  • 9.4.1 MARKET OVERVIEW
  • 9.4.2 MARKET SIZE & FORECAST
  • 9.4.3 MOBILE APPLICATION & SOFTWARE MARKET BY GEOGRAPHY

10 APPLICATION

• 10.1 MARKET SNAPSHOT & GROWTH ENGINE
• 10.2 MARKET OVERVIEW
• 10.3 CARDIOLOGY
  • 10.3.1 MARKET OVERVIEW
  • 10.3.2 MARKET SIZE & FORECAST
  • 10.3.3 CARDIOLOGY MARKET BY GEOGRAPHY
• 10.4 PULMONOLOGY
  • 10.4.1 MARKET OVERVIEW
  • 10.4.2 MARKET SIZE & FORECAST
  • 10.4.3 PULMONOLOGY MARKET BY GEOGRAPHY
• 10.5 NEUROLOGY
  • 10.5.1 MARKET OVERVIEW
  • 10.5.2 MARKET SIZE & FORECAST
  • 10.5.3 NEUROLOGY MARKET BY GEOGRAPHY
• 10.6 OTHER
  • 10.6.1 MARKET OVERVIEW
  • 10.6.2 MARKET SIZE & FORECAST
  • 10.6.3 OTHER MARKET BY GEOGRAPHY

11 CLINICAL PRACTICE

• 11.1 MARKET SNAPSHOT & GROWTH ENGINE
• 11.2 MARKET OVERVIEW
• 11.3 DIAGNOSTIC
  • 11.3.1 MARKET OVERVIEW
  • 11.3.2 MARKET SIZE & FORECAST
  • 11.3.3 DIAGNOSTIC MARKET BY GEOGRAPHY
• 11.4 MONITORING
  • 11.4.1 MARKET OVERVIEW
  • 11.4.2 MARKET SIZE & FORECAST
  • 11.4.3 MONITORING MARKET BY GEOGRAPHY
• 11.5 PROGNOSTIC
  • 11.5.1 MARKET OVERVIEW
  • 11.5.2 MARKET SIZE & FORECAST
  • 11.5.3 PROGNOSTIC MARKET BY GEOGRAPHY
• 11.6 PREDICTIVE
  • 11.6.1 MARKET OVERVIEW
  • 11.6.2 MARKET SIZE & FORECAST
  • 11.6.3 PREDICTIVE MARKET BY GEOGRAPHY
• 11.7 OTHER
  • 11.7.1 MARKET OVERVIEW
  • 11.7.2 MARKET SIZE & FORECAST
  • 11.7.3 OTHER MARKET BY GEOGRAPHY

12 END-USER

• 12.1 MARKET SNAPSHOT & GROWTH ENGINE
• 12.2 MARKET OVERVIEW
• 12.3 HEALTHCARE COMPANIES
  • 12.3.1 MARKET OVERVIEW
  • 12.3.2 MARKET SIZE & FORECAST
  • 12.3.3 HEALTHCARE COMPANIES MARKET BY GEOGRAPHY
• 12.4 HEALTHCARE PROVIDERS
  • 12.4.1 MARKET OVERVIEW
  • 12.4.2 MARKET SIZE & FORECAST
  • 12.4.3 HEALTHCARE PROVIDERS MARKET BY GEOGRAPHY
• 12.5 OTHER
  • 12.5.1 MARKET OVERVIEW
  • 12.5.2 MARKET SIZE & FORECAST
  • 12.5.3 OTHER MARKET BY GEOGRAPHY

13 GEOGRAPHY

• 13.1 MARKET SNAPSHOT & GROWTH ENGINE
• 13.2 GEOGRAPHIC OVERVIEW

14 NORTH AMERICA

• 14.1 MARKET OVERVIEW
• 14.2 MARKET SIZE & FORECAST
  • 14.2.1 NORTH AMERICA MARKET BY PRODUCT TYPE
  • 14.2.2 NORTH AMERICA MARKET BY APPLICATION
  • 14.2.3 NORTH AMERICA MARKET BY CLINICAL PRACTICE
  • 14.2.4 NORTH AMERICA MARKET BY END-USER
• 14.3 KEY COUNTRIES
• 14.4 US: MARKET SIZE & FORECAST
• 14.5 CANADA: MARKET SIZE & FORECAST

15 EUROPE

• 15.1 MARKET OVERVIEW
• 15.2 MARKET SIZE & FORECAST
  • 15.2.1 EUROPE MARKET BY PRODUCT TYPE
  • 15.2.2 EUROPE MARKET BY APPLICATION
  • 15.2.3 EUROPE MARKET BY CLINICAL PRACTICE
  • 15.2.4 EUROPE MARKET BY END-USER
• 15.3 KEY COUNTRIES
• 15.4 GERMANY: MARKET SIZE & FORECAST
• 15.5 UK: MARKET SIZE & FORECAST
• 15.6 FRANCE: MARKET SIZE & FORECAST
• 15.7 ITALY: MARKET SIZE & FORECAST
• 15.8 SPAIN: MARKET SIZE & FORECAST
• 15.9 RUSSIA: MARKET SIZE & FORECAST
• 15.10 NETHERLANDS: MARKET SIZE & FORECAST

16 APAC

• 16.1 MARKET OVERVIEW
• 16.2 MARKET SIZE & FORECAST
  • 16.2.1 APAC MARKET BY PRODUCT TYPE
  • 16.2.2 APAC MARKET BY APPLICATION
  • 16.2.3 APAC MARKET BY CLINICAL PRACTICE
  • 16.2.4 APAC MARKET BY END-USER
• 16.3 KEY COUNTRIES
• 16.4 JAPAN: MARKET SIZE & FORECAST
• 16.5 CHINA: MARKET SIZE & FORECAST
• 16.6 INDIA: MARKET SIZE & FORECAST
• 16.7 SOUTH KOREA: MARKET SIZE & FORECAST
• 16.8 AUSTRALIA: MARKET SIZE & FORECAST

17 LATIN AMERICA

• 17.1 MARKET OVERVIEW
• 17.2 MARKET SIZE & FORECAST
  • 17.2.1 LATIN AMERICA MARKET BY PRODUCT TYPE
  • 17.2.2 LATIN AMERICA MARKET BY APPLICATION
  • 17.2.3 LATIN AMERICA MARKET BY CLINICAL PRACTICE
  • 17.2.4 LATIN AMERICA MARKET BY END-USER
• 17.3 KEY COUNTRIES
• 17.4 BRAZIL: MARKET SIZE & FORECAST
• 17.5 MEXICO: MARKET SIZE & FORECAST
• 17.6 ARGENTINA: MARKET SIZE & FORECAST
• 17.7 COLOMBIA: MARKET SIZE & FORECAST

18 MIDDLE EAST & AFRICA

• 18.1 MARKET OVERVIEW
• 18.2 MARKET SIZE & FORECAST
  • 18.2.1 MIDDLE EAST & AFRICA MARKET BY PRODUCT TYPE
  • 18.2.2 MIDDLE EAST & AFRICA MARKET BY APPLICATION
  • 18.2.3 MIDDLE EAST & AFRICA MARKET BY CLINICAL PRACTICE
  • 18.2.4 MIDDLE EAST & AFRICA MARKET BY END-USER
• 18.3 KEY COUNTRIES
• 18.4 TURKEY: MARKET SIZE & FORECAST
• 18.5 SAUDI ARABIA: MARKET SIZE & FORECAST
• 18.6 UAE: MARKET SIZE & FORECAST
• 18.7 SOUTH AFRICA: MARKET SIZE & FORECAST

19 COMPETITIVE LANDSCAPE

• 19.1 COMPETITION OVERVIEW
• 19.2 MARKET SHARE ANALYSIS
  • 19.2.1 ACTIGRAPH
  • 19.2.2 ALIVECOR
  • 19.2.3 AMGEN
  • 19.2.4 BIOGEN
  • 19.2.5 KONEKSA HEALTH

20 KEY COMPANY PROFILES

• 20.1 ACTIGRAPH
  • 20.1.1 BUSINESS OVERVIEW
  • 20.1.2 PRODUCT OFFERINGS
  • 20.1.3 KEY STRATEGIES
  • 20.1.4 KEY STRENGTHS
  • 20.1.5 KEY OPPORTUNITIES
• 20.2 ALIVECOR
  • 20.2.1 BUSINESS OVERVIEW
  • 20.2.2 PRODUCT OFFERINGS
  • 20.2.3 KEY STRATEGIES
  • 20.2.4 KEY STRENGTHS
  • 20.2.5 KEY OPPORTUNITIES
• 20.3 AMGEN
  • 20.3.1 BUSINESS OVERVIEW
  • 20.3.2 PRODUCT OFFERINGS
  • 20.3.3 KEY STRATEGIES
  • 20.3.4 KEY STRENGTHS
  • 20.3.5 KEY OPPORTUNITIES
• 20.4 BIOGEN
  • 20.4.1 BUSINESS OVERVIEW
  • 20.4.2 PRODUCT OFFERINGS
  • 20.4.3 KEY STRATEGIES
  • 20.4.4 KEY STRENGTHS
  • 20.4.5 KEY OPPORTUNITIES
• 20.5 KONEKSA HEALTH
  • 20.5.1 BUSINESS OVERVIEW
  • 20.5.2 PRODUCT OFFERINGS
  • 20.5.3 KEY STRATEGIES
  • 20.5.4 KEY STRENGTHS
  • 20.5.5 KEY OPPORTUNITIES

21 OTHER PROMINENT VENDORS

• 21.1 ADHERIUM
  • 21.1.1 BUSINESS OVERVIEW
  • 21.1.2 PRODUCT OFFERINGS
• 21.2 AURAL ANALYTICS
  • 21.2.1 BUSINESS OVERVIEW
  • 21.2.2 PRODUCT OFFERINGS
• 21.3 BIOFOURMIS
  • 21.3.1 BUSINESS OVERVIEW
  • 21.3.2 PRODUCT OFFERINGS
• 21.4 CLARIO
  • 21.4.1 BUSINESS OVERVIEW
  • 21.4.2 PRODUCT OFFERINGS
• 21.5 EMPATICA
  • 21.5.1 BUSINESS OVERVIEW
  • 21.5.2 PRODUCT OFFERINGS
• 21.6 FEEL THERAPEUTICS
  • 21.6.1 BUSINESS OVERVIEW
  • 21.6.2 PRODUCT OFFERINGS
• 21.7 GERO.AI
  • 21.7.1 BUSINESS OVERVIEW
  • 21.7.2 PRODUCT OFFERINGS
• 21.8 IXICO
  • 21.8.1 BUSINESS OVERVIEW
  • 21.8.2 PRODUCT OFFERINGS
• 21.9 OBVIO HEALTH
  • 21.9.1 BUSINESS OVERVIEW
  • 21.9.2 PRODUCT OFFERINGS
• 21.10 OWKIN
  • 21.10.1 BUSINESS OVERVIEW
  • 21.10.2 PRODUCT OFFERINGS
• 21.11 PRECORDIOR
  • 21.11.1 BUSINESS OVERVIEW
  • 21.11.2 PRODUCT OFFERINGS
• 21.12 RESAPP HEALTH
  • 21.12.1 BUSINESS OVERVIEW
  • 21.12.2 PRODUCT OFFERINGS
• 21.13 ROCKLEY PHOTONICS
  • 21.13.1 BUSINESS OVERVIEW
  • 21.13.2 PRODUCT OFFERINGS
• 21.14 SONDE HEALTH
  • 21.14.1 BUSINESS OVERVIEW
  • 21.14.2 PRODUCT OFFERINGS
• 21.15 VIVOSENSE
  • 21.15.1 BUSINESS OVERVIEW
  • 21.15.2 PRODUCT OFFERINGS

22 REPORT SUMMARY

• 22.1 KEY TAKEAWAYS
• 22.2 STRATEGIC RECOMMENDATIONS

23 QUANTITATIVE SUMMARY

• 23.1 MARKET BY PRODUCT TYPE
  • 23.1.1 NORTH AMERICA MARKET BY PRODUCT TYPE
  • 23.1.2 EUROPE MARKET BY PRODUCT TYPE
  • 23.1.3 APAC MARKET BY PRODUCT TYPE
  • 23.1.4 LATIN AMERICA MARKET BY PRODUCT TYPE
  • 23.1.5 MIDDLE EAST & AFRICA MARKET BY PRODUCT TYPE
• 23.2 MARKET BY APPLICATION
  • 23.2.1 NORTH AMERICA MARKET BY APPLICATION
  • 23.2.2 EUROPE MARKET BY APPLICATION
  • 23.2.3 APAC MARKET BY APPLICATION
  • 23.2.4 LATIN AMERICA MARKET BY APPLICATION
  • 23.2.5 MIDDLE EAST & AFRICA MARKET BY APPLICATION
• 23.3 MARKET BY CLINICAL PRACTICE
  • 23.3.1 NORTH AMERICA MARKET BY CLINICAL PRACTICE
  • 23.3.2 EUROPE MARKET BY CLINICAL PRACTICE
  • 23.3.3 APAC MARKET BY CLINICAL PRACTICE
  • 23.3.4 LATIN AMERICA MARKET BY CLINICAL PRACTICE
  • 23.3.5 MIDDLE EAST & AFRICA MARKET BY CLINICAL PRACTICE
• 23.4 MARKET BY END-USER
  • 23.4.1 NORTH AMERICA MARKET BY END-USER
  • 23.4.2 EUROPE MARKET BY END-USER
  • 23.4.3 APAC MARKET BY END-USER
  • 23.4.4 LATIN AMERICA MARKET BY END-USER
  • 23.4.5 MIDDLE EAST & AFRICA MARKET BY END-USER
• 23.5 MARKET BY GEOGRAPHY
  • 23.5.1 WEARABLES & SENSORS MARKET BY GEOGRAPHY
  • 23.5.2 MOBILE APPLICATION & SOFTWARE MARKET BY GEOGRAPHY
  • 23.5.3 CARDIOLOGY MARKET BY GEOGRAPHY
  • 23.5.4 PULMONOLOGY MARKET BY GEOGRAPHY
  • 23.5.5 NEUROLOGY MARKET BY GEOGRAPHY
  • 23.5.6 OTHER MARKET BY GEOGRAPHY
  • 23.5.7 DIAGNOSTIC MARKET BY GEOGRAPHY
  • 23.5.8 MONITORING MARKET BY GEOGRAPHY
  • 23.5.9 PROGNOSTIC MARKET BY GEOGRAPHY
  • 23.5.10 PREDICTIVE MARKET BY GEOGRAPHY
  • 23.5.11 OTHER MARKET BY GEOGRAPHY
  • 23.5.12 HEALTHCARE COMPANIES MARKET BY GEOGRAPHY
  • 23.5.13 HEALTHCARE PROVIDERS MARKET BY GEOGRAPHY
  • 23.5.14 OTHER MARKET BY GEOGRAPHY

24 APPENDIX

• 24.1 RESEARCH METHODOLOGY
• 24.2 RESEARCH PROCESS
• 24.3 REPORT ASSUMPTIONS & CAVEATS
  • 24.3.1 KEY CAVEATS
  • 24.3.2 CURRENCY CONVERSION
• 24.4 ABBREVIATIONS